Efaproxiral

• Description:

  Efaproxiral is a haemoglobin (Hb) synthetic allosteric modifier, decreases Hb-oxygen (O2) binding affinity and enhances oxygenation of hypoxic tumours during radiation therapy [1].

• Product Name Alternative:

  RSR13

• UNSPSC:

  12352005

• Hazard Statement:

  H302

• Target:

  Reactive Oxygen Species (ROS)

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Efaproxiral.html

• Concentration:

  10mM

• Purity:

  99.94

• Solubility:

  DMSO : ≥ 150 mg/mL

• Smiles:

  CC(C)(OC1=CC=C(CC(NC2=CC(C)=CC(C)=C2)=O)C=C1)C(O)=O

• Molecular Formula:

  C20H23NO4

• Molecular Weight:

  341.40

• Precautions:

  H302

• References & Citations:

  [1]Stea B, et al. Efaproxiral red blood cell concentration predicts efficacy in patients with brain metastases. Br J Cancer. 2006 Jun 19;94 (12) :1777-1784.|[2]Abraham DJ, et al. Allosteric modifiers of hemoglobin: 2-[4-[[ (3,5-disubstituted anilino) carbonyl]methyl]phenoxy]-2-methylpropionic acid derivatives that lower the oxygen affinity of hemoglobin in red cell suspensions, in whole blood, and in vivo in rats. Biochemistry. 1992 Sep 29;31 (38) :9141-9.|[3]Hou H, et al. The effects of Efaproxyn (efaproxiral) on subcutaneous RIF-1 tumor oxygenation and enhancement of radiotherapy-mediated inhibition of tumor growth in mice. Radiat Res. 2007 Aug;168 (2) :218-25.|[4]Hou H, et al. Increased oxygenation of intracranial tumors by efaproxyn (efaproxiral), an allosteric hemoglobin modifier: In vivo EPR oximetry study. Int J Radiat Oncol Biol Phys. 2005 Apr 1;61 (5) :1503-9.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 3

• CAS Number:

  [131179-95-8]